Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 4
Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
Panelists discuss how medical professionals balance maximizing progression-free survival with preserving future treatment options by considering disease biology, resistance mechanisms, and patient factors. At first progression, the NCCN recommends continuing current therapy or switching to amivantamab with a platinum doublet, based on mutation status, prior response, toxicity, and patient preferences.
Video Player is loading.
Video content above is prompted by the following:
- How do you weigh the benefits of selecting therapies that maximize progression-free survival against the importance of preserving future treatment options?
- At first progression, NCCN recommends either continuing the patient’s current systemic therapy or changing therapy to amivantamab combined with a platinum doublet. What are the most important clinical factors to consider when making this decision?
